U.S. Bioscience Firm’s Anti-Inflammatory Compound Licensed In Japan
This article was originally published in The Rose Sheet
Executive Summary
A licensing deal between U.S. private biotech firm Signum Biosciences and Japanese skin care manufacturer Rohto Pharmaceutical will yield a range of anti-inflammatory skin care products in the Japanese market, the firms report Sept. 17